

Andrea Bacigalupo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6305002/publications.pdf>

Version: 2024-02-01

104
papers

10,458
citations

57752

44
h-index

34984

98
g-index

105
all docs

105
docs citations

105
times ranked

7586
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining the Intensity of Conditioning Regimens: Working Definitions. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1628-1633.	2.0	1,419
2	Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. <i>Blood</i> , 2003, 102, 814-819.	1.4	515
3	Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). <i>Blood</i> , 2001, 98, 2942-2947.	1.4	487
4	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. <i>Leukemia</i> , 2018, 32, 1057-1069.	7.2	415
5	Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. <i>Blood</i> , 2001, 98, 972-978.	1.4	342
6	Thymoglobulin Prevents Chronic Graft-versus-Host Disease, Chronic Lung Dysfunction, and Late Transplant-Related Mortality: Long-Term Follow-Up of a Randomized Trial in Patients Undergoing Unrelated Donor Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 560-565.	2.0	326
7	Unmanipulated Haploidentical Bone Marrow Transplantation and Posttransplantation Cyclophosphamide for Hematologic Malignancies after Myeloablative Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 117-122.	2.0	324
8	Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. <i>Lancet Haematology</i> , 2020, 7, e157-e167.	4.6	319
9	Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2007, 92, 11-18.	3.5	318
10	How I treat acquired aplastic anemia. <i>Blood</i> , 2017, 129, 1428-1436.	1.4	279
11	Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. <i>Blood</i> , 2007, 110, 1397-1400.	1.4	260
12	Unmanipulated Haploidentical Transplants Compared with Other Alternative Donors and Matched Sibling Grafts. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1573-1579.	2.0	259
13	Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. <i>Lancet Oncology</i> , 2008, 9, 831-839.	10.7	244
14	Treatment of acquired severe aplastic anemia: Bone marrow transplantation compared with immunosuppressive therapy-the European group for blood and marrow transplantation experience. <i>Seminars in Hematology</i> , 2000, 37, 69-80.	3.4	223
15	Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2016, 34, 3627-3637.	1.6	204
16	Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. <i>Blood</i> , 2005, 105, 4115-4119.	1.4	194
17	Blood Stream Infections in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Reemergence of Gram-Negative Rods and Increasing Antibiotic Resistance. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 47-53.	2.0	189
18	A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2011, 117, 4434-4441.	1.4	187

#	ARTICLE	IF	CITATIONS
19	Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. <i>Haematologica</i> , 2010, 95, 976-982.	3.5	183
20	Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. <i>Haematologica</i> , 2012, 97, 1142-1148.	3.5	167
21	Treatment of acquired aplastic anemia: Bone marrow transplantation compared with immunosuppressive therapy [mdash] The European Group for Blood and Marrow Transplantation Experience. <i>Seminars in Hematology</i> , 2000, 37, 69-80.	3.4	160
22	Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. <i>Blood</i> , 2006, 107, 4177-4181.	1.4	158
23	Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. <i>Blood</i> , 2012, 119, 5391-5396.	1.4	156
24	Similar outcome of upfront unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the <scp>UK</scp> Paediatric <scp>BMT</scp> Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of <scp>EBMT</scp>. <i>British Journal of Haematology</i> , 2015, 171, 585-594.	2.5	146
25	Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1525-1536.	10.7	143
26	Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 872-880.	2.0	141
27	Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis. <i>Haematologica</i> , 2015, 100, 696-702.	3.5	141
28	Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. <i>British Journal of Haematology</i> , 2001, 112, 219-227.	2.5	137
29	MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. <i>Blood</i> , 2014, 124, 1183-1191.	1.4	135
30	Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021, 39, 1223-1233.	1.6	127
31	Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Haematologica</i> , 2008, 93, 1514-1522.	3.5	121
32	Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. <i>Haematologica</i> , 2009, 94, 1312-1315.	3.5	118
33	Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. <i>Lancet Oncology</i> , The, 2010, 11, 331-338.	10.7	113
34	Post-transplant cyclophosphamide <i>versus</i> anti-thymocyte globulin as graft- <i>versus</i> -host disease prophylaxis in haploidentical transplant. <i>Haematologica</i> , 2017, 102, 401-410.	3.5	109
35	Boost of CD34+ -selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. <i>Haematologica</i> , 2006, 91, 935-40.	3.5	95
36	Outcomes following HSCT Using Fludarabine, Busulfan, and Thymoglobulin: A Matched Comparison to Allogeneic Transplants Conditioned with Busulfan and Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 993-1003.	2.0	89

#	ARTICLE	IF	CITATIONS
37	Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA. <i>British Journal of Haematology</i> , 2009, 144, 933-945.	2.5	80
38	CD34 Selected Cells for the Treatment of Poor Graft Function after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1440-1443.	2.0	72
39	Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of $WT1$ expression. <i>British Journal of Haematology</i> , 2013, 160, 503-509.	2.5	64
40	Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2004, 89, 1238-47.	3.5	62
41	Rituximab Treatment for Epstein-Barr Virus DNAemia after Alternative-Donor Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 901-907.	2.0	59
42	Improved Outcome of Alternative Donor Transplantations in Patients with Myelofibrosis: From Unrelated to Haploidentical Family Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 324-329.	2.0	56
43	Primary Prophylaxis of Invasive Fungal Diseases in Allogeneic Stem Cell Transplantation: Revised Recommendations from a Consensus Process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1080-1088.	2.0	54
44	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2020, 105, 47-58.	3.5	51
45	A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1243-1249.	2.0	49
46	Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia. <i>International Journal of Hematology</i> , 2016, 104, 168-174.	1.6	46
47	The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis. <i>Blood Advances</i> , 2017, 1, 669-680.	5.2	43
48	Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved?. <i>Blood</i> , 2018, 131, 1989-1992.	1.4	43
49	Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1242-1246.	2.0	41
50	Pre-Engraftment Bloodstream Infections after Allogeneic Hematopoietic Cell Transplantation: Impact of T Cell-Replete Transplantation from a Haploidentical Donor. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 109-118.	2.0	41
51	RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT. <i>Oncotarget</i> , 2016, 7, 43027-43038.	1.8	40
52	Late Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation: Diagnosis, Monitoring, Prevention, and Treatment. <i>Seminars in Hematology</i> , 2012, 49, 15-24.	3.4	39
53	Bone marrow or peripheral blood as a source of stem cells for allogeneic transplantation. <i>Haematologica</i> , 2002, 87, 4-8.	3.5	38
54	Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High-Dose Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 119-126.	2.0	37

#	ARTICLE	IF	CITATIONS
55	Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1223-1231.	3.5	34
56	Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 1906-1917.	2.4	33
57	First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001-2012. <i>American Journal of Hematology</i> , 2018, 93, 643-648.	4.1	32
58	Alternative donor transplants for severe aplastic anemia. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 467-473.	2.5	30
59	Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. <i>Blood Advances</i> , 2020, 4, 3900-3912.	5.2	30
60	Haemopoietic stem cell transplants: the impact of haemorrhagic complications. <i>Blood Reviews</i> , 2003, 17, S6-S10.	5.7	29
61	Steroid treatment of acute graft-versus-host disease grade I: a randomized trial. <i>Haematologica</i> , 2017, 102, 2125-2133.	3.5	27
62	Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, e348-e351.	3.5	26
63	Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 1987-1994.	2.4	25
64	Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 932-940.	2.0	25
65	Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1915-1922.	2.0	24
66	Alternative donor transplants for severe aplastic anemia: current experience. <i>Seminars in Hematology</i> , 2016, 53, 115-119.	3.4	23
67	2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management. <i>American Journal of Hematology</i> , 2021, 96, 1532-1538.	4.1	23
68	Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients. <i>Bone Marrow Transplantation</i> , 2019, 54, 708-712.	2.4	22
69	Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody - Beigomab. <i>Bone Marrow Transplantation</i> , 2020, 55, 1580-1587.	2.4	21
70	Haploidentical donor transplants for severe aplastic anemia. <i>Seminars in Hematology</i> , 2019, 56, 190-193.	3.4	19
71	Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 698-703.	2.0	19
72	Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study. <i>International Journal of Hematology</i> , 2021, 114, 228-234.	1.6	16

#	ARTICLE	IF	CITATIONS
73	Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen. <i>American Journal of Hematology</i> , 2021, 96, 234-240.	4.1	14
74	Second haploidentical stem cell transplantation for primary graft failure. <i>Bone Marrow Transplantation</i> , 2021, 56, 1291-1296.	2.4	14
75	Antithymocyte globulin and cyclosporin: standard of care also for older patients with aplastic anemia. <i>Haematologica</i> , 2019, 104, 215-216.	3.5	11
76	Unrelated cord blood transplantation and post-transplant cyclophosphamide. <i>Haematologica</i> , 2019, 104, e77-e78.	3.5	10
77	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OF THE ELDERLY: REVIEW OF THE LITERATURE AND PERSPECTIVES.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020081.	1.3	10
78	Bone marrow haploidentical transplant with post-transplantation cyclophosphamide: does graft cell content have an impact on main clinical outcomes?. <i>Cytotherapy</i> , 2020, 22, 158-165.	0.7	10
79	Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021. <i>Frontiers in Immunology</i> , 2021, 12, 637512.	4.8	9
80	Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , 2021, 107, 573-582.	2.2	7
81	Use of Bone Marrow or Peripheral Blood Stem Cell Grafts in Non T Cell Depleted Haploidentical Transplants Using Post-Transplant Cyclophosphamide, an ALWP-EBMT Analysis. <i>Blood</i> , 2016, 128, 1165-1165.	1.4	7
82	Nutritional status and quality of life in adults undergoing allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2022, 116, 266-275.	1.6	6
83	Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants. <i>Bone Marrow Transplantation</i> , 2018, 53, 1560-1567.	2.4	5
84	Bone marrow transplantation for acquired aplastic anemia: What's new. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101284.	1.7	5
85	Upfront Alternative Donor Transplant versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack a Fully HLA-Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies, on Behalf of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 105.e1-105.e7.	1.2	5
86	Reducing infectious complications after allogeneic stem cell transplant. <i>Expert Review of Hematology</i> , 2020, 13, 1235-1251.	2.2	4
87	Hemorrhagic cystitis in allogeneic stem cell transplantation: a role for age and prostatic hyperplasia. <i>Supportive Care in Cancer</i> , 2022, 30, 4953-4959.	2.2	4
88	Antithymocyte globulin and transplants for aplastic anemia. <i>Haematologica</i> , 2017, 102, 1137-1138.	3.5	3
89	Antithymocyte Globulin in the Conditioning Regimen: Why Not?. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 597-598.	2.0	2
90	Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome. <i>Journal of Clinical Immunology</i> , 2018, 38, 7-9.	3.8	2

#	ARTICLE	IF	CITATIONS
91	Identifying the Best Haploidentical Donor: Are We There?. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 638-640.	2.0	2
92	High versus low dose cyclosporineâ€A, after allogeneic marrow transplantation in leukemia: Longâ€term followâ€up of a randomized study. <i>American Journal of Hematology</i> , 2018, 93, E185.	4.1	2
93	ABO Mismatch in Allogeneic Hematopoietic Stem Cell Transplant: Effect on Short- and Long-term Outcomes. <i>Transplantation Direct</i> , 2021, 7, e724.	1.6	2
94	Haploidentical HSCT. , 2019, , 479-486.		2
95	IS ALLOGENEIC TRANPLANTATION AN OPTION IN PATIENTS AFFECTED BY CONCURRENT MYELOFIBROSIS AND CHRONIC MYELOID LEUKEMIA (CML)?. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2021, 13, e2021062.	1.3	2
96	Failure to effectively treat chronic graft-versus-host disease: a strong call for prevention. <i>Haematologica</i> , 2016, 101, e214-e215.	3.5	1
97	A 30-month-old boy with aplastic anemia caused by electrocution. <i>Annals of Hematology</i> , 2020, 99, 2439-2440.	1.8	1
98	High Predictive Value of Pre Transplant Minimal Residual Disease Assessment By Combining WT1 Expression and Flow Cytometry in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2029-2029.	1.4	1
99	The EHA Research Roadmap: Hematopoietic Stem Cells and Allotransplantation. <i>HemaSphere</i> , 2022, 6, e0714.	2.7	1
100	Myeloablative Versus Nonmyeloablative Conditioning Regimen in Haploidentical Transplantation: Does It Matter and How Best to Select Between the Two?. , 2018, , 159-171.		0
101	The complexity of stem cell transplants: can we improve our understanding?. <i>Haematologica</i> , 2018, 103, 1417-1418.	3.5	0
102	Trajectory of lung function to pleuroparenchymal fibroelastosis late after haematopoietic stem-cell transplantation. <i>Respiratory Medicine Case Reports</i> , 2019, 28, 100915.	0.4	0
103	Unrelated Cord Blood Transplantation and Post-Transplant Cyclophosphamide (PT-CY). <i>Blood</i> , 2019, 134, 3332-3332.	1.4	0
104	Established Drugs and Emerging Targets in Aplastic Anemia. , 2021, , .		0